Radiation-based therapies

CLS has developed molecular-based blood tests to predict whether a patient should receive radiation therapy including peptide receptor radionuclide therapy (PRRT) e.g., 177Lutathera. It is developing a test for 177Lu-PSMA. This modality of targeted therapy is used in the treatment of prostate cancer, myeloma and neuroendocrine cancers. The accuracy of PRRT predictive tests of efficacy ranges from 94-97%.

Medical research scientist is using desktop computer conducting DNA experiments under an electron microscope and reviewing results.

Residual or metastatic disease

CLS is developing molecular-based methods that are able to define the efficacy of surgery (tumor removal) and detect evidence of residual disease in metastatic sites like lymph nodes, the liver or bone marrow. Current approaches based on imaging require ~0.5cm size lesions (~6,000,000 cells) before they can be detected. Preoperative morphologic imaging techniques detect less than 50% of hepatic metastases and all tumors are likely under-staged. Results using CLS technology identified metastases in 50% of lymph nodes classified by current approaches as “disease-free”. The CLS approach is accurate, highly sensitive and can be used to identify minimal residual disease and accurately define disease stage. Such information facilitates early therapeutic intervention and is potentially applicable to a range of cancers including breast, colon, lung, pancreatic melanoma, myeloma, NET and prostate cancer.

Customers are thrilled with the results we have achieved.

Abstract genome sequence and chromosome architecture map.